Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-Year results of International Breast Cancer Study Group Trial IV

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4517-4523

  Crivellari, Diana ^a   Price, Karen ^b   Gelber, Richard D ^b   Castiglione Gertsch, Monica ^b   Rudenstam, Carl Magnus ^b   Lindtner, Jurij ^b   Fey, Martin F ^b   Senn, Hans Jörg ^b   Coates, Alan S ^b   Collins, John ^b   Goldhirsch, Aron ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LOW DRUG DOSE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BREAST TUMOR; COMPARATIVE STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 1542753651     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.559     Document Type: Article

References (37)

1. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994
2. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
4. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
5. Castiglione M, Gelber RD, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: Competing causes of mortality. J Clin Oncol 8:519-526, 1990
6. Ludwig Breast Cancer Study Group: Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1:1256-1260, 1984
7. Cummings FJ, Gray R, Davis TE, et al: Adjuvant tamoxifen treatment of elderly women with stage II breast cancer: A double-blind comparison with placebo. Ann Intern Med 103:324-329, 1985
8. Cummings FJ, Gray R, Tormey DC, et al: Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death. J Clin Oncol 11:3-4, 1993
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
11. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
12. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 169
13. Bonetti M, Gelber RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595-2609, 2000
14. Bonetti M, Gelber RD, Goldhirsch A, et al: Features that predict responsiveness to chemotherapy and endocrine therapies. The Breast 10:147-157, 2001 (suppl 3)
15. Stewart JF, Rubens RD, King RJB, et al: Contribution of prednisolone to the primary endocrine therapy of advanced breast cancer. Eur J Cancer Clin Oncol 18:1307-1314, 1982
16. Fisher B, Brown A, Wolmark M, et al: Prolonging tamoxifen therapy for primary breast cancer. Ann Intern Med 106:649-654, 1987
17. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1647, 1999
18. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355:1757-1770, 2000
19. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
20. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
21. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85:1398-1406, 1993
22. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294, 1991
23. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 311:977-980, 1995
24. Fisher B, Constantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320:479-484, 1989
25. Jacquot C, Graterol R, Bariety J, et al: Thrombotic accidents during tamoxifen therapy for metastatic breast cancer. N Engl J Med 304:1042, 1981
26. Lipton A, Harvey Y, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984
27. Wall JG, Weiss RB, Norton L, et al: Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A Cancer and Leukemia Group B study. Am J Med 87:501-504, 1989
28. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
29. Pritchard KI, Paterson AH, Paul NA, et al: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 14:2731-2737, 1996
30. Ragaz J, Coldman A: Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 16:2018-2024, 1998
31. Bonneterre J, Thürlimann B, Robertson JFR, et al: Anastrozole versus tamoxifen tolerability as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18:3748-3757, 2000
32. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American Multicenter Randomized Trial. J Clin Oncol 18:3758-3767, 2000
33. Mouridsen H, Gershanovic M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
34. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and /or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
35. The ATAC Trialists Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
36. Extermann M: Assessment of the older cancer patient. ASCO Educational Book, Spring: 353-360, 1999
37. Wolff AC, Abeloff MD: Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: It ain't necessarily so. J Natl Cancer Inst 94:1041-1043, 2002